A company based in Akureyri, north Iceland, could become the town’s first unicorn, according to a report in Viðskiptablaðið. The business is said to be developing drugs targeting markets whose annual revenues exceed $100 billion. No additional information about the company or its specific drug projects has been made public.
Viðskiptablaðið, which first reported the story, highlighted the potential for the company to reach a billion-dollar valuation if its drug development succeeds in entering these major pharmaceutical markets. However, the company’s name and detailed statements about the business or its leadership have not been disclosed.
Akureyri, sometimes called the Capital of North Iceland, is the largest town outside Iceland’s capital area and serves as an important regional centre and port. While the region has a long history of fishing and maritime industries, the rise of a possible unicorn would mark a significant development for the area’s tech and pharmaceutical sectors.
Sources
- Viðskiptablaðið (first reported) in Icelandic
Image: Christine Zenino from Chicago, US / Wikimedia Commons (CC BY 2.0) · licence, original (resized) Illustrative image.
.jpg){kind=link}